 |
|
|
| |
A Randomized Phase 3 Trial of
Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Ira M. Jacobson1, Tarik Asselah2, Ronald Nahass3, Bal R. Bhandari4, Albert Tran5, Robert H. Hyland6, Luisa M. Stamm6, Hadas Dvory-Sobol6, Yanni Zhu6, Diana M. Brainard6, G. Mani Subramanian6, John G. McHutchison6, Stephen Shafran7, Mitchell Davis8, Catherine A. Stedman9, Eric Lawitz10, Edward J. Gane11
1. Mount Sinai Beth Israel, New York, NY; 2. Hôpital Beaujon, AP-HP, INSERM UMR 1149, Université Paris Diderot, Clichy, France; 3. Infectious
Disease Care, Hillsborough, NJ; 4. Gastroenterology & Nutritional Medical Services, Bastrop, LA; 5. Centre Hospitalier Universitaire de Nice, Nice,
France; 6. Gilead Sciences, Inc., Foster City, CA; 7. University of Alberta, Edmonton, Alberta, Canada; 8. Digestive Care-South Florida Center of
Gastroenterology, Wellington, FL; 9. Christchurch Hospital, Christchurch, New Zealand; 10. Texas Liver Institute, University of Texas Health
Science Center, San Antonio, TX; 11. Auckland Clinical Studies, Auckland, New Zealand
|
| |
|
|
|
|
|
